ArticleLung2017
Volatile Organic Compounds in Exhaled Breath of Idiopathic Pulmonary Fibrosis for Discrimination from Healthy Subjects.
Article in Lung, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Breath biomarkers in idiopathic pulmonary fibrosis: a systematic review.Respiratory research · 2019Pooled it
- Exhaled Breath Analysis for Detection of Interstitial Lung Diseases Using Real-Time PTR-TOF-MS.International journal of molecular sciences · 2026Article
- The Role of Exhaled Breath Analyses in Interstitial Lung Disease.Diagnostics (Basel, Switzerland) · 2025Review
- Exploring exhaled volatile organic compounds as potential biomarkers in anti-MDA5 antibody-positive interstitial lung disease.Molecular and cellular biochemistry · 2025Article
- Targeted Analysis of VOCS in Exhaled Breath of Coal Workers' Pneumoconiosis Patients, An Exploratory Study.China CDC weekly · 2024Article
- Combination of real-time and hyphenated mass spectrometry for improved characterisation of exhaled breath biomarkers in clinical research.Analytical and bioanalytical chemistry · 2024Article
- Article
- The role of volatile organic compounds for assessing characteristics and severity of non-cystic fibrosis bronchiectasis: an observational study.Frontiers in medicine · 2024Article
- Article
- Novel diagnostic techniques in interstitial lung disease.Frontiers in medicine · 2023Review
- Variation of volatile organic compound levels within ambient room air and its impact upon the standardisation of breath sampling.Scientific reports · 2022Article
- The use of exhaled air analysis in discriminating interstitial lung diseases: a pilot study.Respiratory research · 2022Observational
- Breathomics for the clinician: the use of volatile organic compounds in respiratory diseases.Thorax · 2021Review
- BALSAM-An Interactive Online Platform for Breath Analysis, Visualization and Classification.Metabolites · 2020Article
- Exhaled Volatile Organic Compounds during Inflammation Induced by TNF-α in Ventilated Rats.Metabolites · 2020Article
- Volatile organic compounds in ventilated critical care patients: a systematic evaluation of cofactors.BMC pulmonary medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose Human breath analysis is proposed with increasing frequency as a useful tool in clinical application. We performed this study to find the characteristic volatile organic compounds (VOCs) in the exhaled breath of patients with idiopathic pulmonary fibrosis (IPF) for discrimination from healthy subjects. Methods VOCs in the exhaled breath of 40 IPF patients and 55 healthy controls were measured using a multi-capillary column and ion mobility spectrometer. The patients were examined by pulmonary function tests, blood gas analysis, and serum biomarkers of interstitial pneumonia. Results We detected 85 VOC peaks in the exhaled breath of IPF patients and controls. IPF patients showed 5 significant VOC peaks; p-cymene, acetoin, isoprene, ethylbenzene, and an unknown compound. The VOC peak of p-cymene was significantly lower (p < 0.001), while the VOC peaks of acetoin, isoprene, ethylbenzene, and the unknown compound were significantly higher (p < 0.001 for all) compared with the peaks of controls. Comparing VOC peaks with clinical parameters, negative correlations with VC (r =-0.393, p = 0.013), %VC (r =-0.569, p < 0.001), FVC (r = -0.440, p = 0.004), %FVC (r =-0.539, p < 0.001), DLco (r =-0.394, p = 0.018), and %DLco (r =-0.413, p = 0.008) and a positive correlation with KL-6 (r = 0.432, p = 0.005) were found for p-cymene. Conclusion We found characteristic 5 VOCs in the exhaled breath of IPF patients. Among them, the VOC peaks of p-cymene were related to the clinical parameters of IPF. These VOCs may be useful biomarkers of IPF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.